OCULJPMPresentationJan2025

Ocular Therapeutix Corporate Overview43rdAnnual J.P. Morgan Healthcare Conference | January 2025Retina experience redefined.2Forward Looking Statements and Disclaimers2Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company’s product candidates, including the design of, and the timing of the enrollment of the Company’s SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company’s plans to advance the development of AXPAXLI and its other product candidates, including in additional indications such as NPDR; the size of potential markets for the Company’s product candidates; the potential utility or adoption, if approved, of any of the Company's product candidates; the sufficiency of the Company’s cash resources; and other statements containing the words "anticipate", "believe”, "estimate”, "expect”, "intend", “designed”, "goa